Discovery and efficacy study of an ALK inhibitor AMX6001 in anaplastic large cell lymphoma Karpas299 mice models
Anaplastic lymphoma kinase (ALK) is an attractive therapeutic target for the treatment of anaplastic large cell lymphoma (ALCL). We identified novel deuterated 2,4-diarylamino pyrimidine compounds as potent ALK inhibitors. The compound 9 (AMX6001) showed better in vitro activity against ALK and NPM-...
Saved in:
Main Authors: | Debasis Das (Author), Lingzhi Xie (Author), Dandan Qiao (Author), Yuxi Cao (Author), Jianhe Jia (Author), Yong Li (Author), Jian Hong (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pathobiology of ALK-negative anaplastic large cell lymphoma
by: Stefano A. Pileri, et al.
Published: (2011) -
Educational Case: ALK-Negative Anaplastic Large Cell Lymphoma
by: Akira Satou MD, PhD, et al.
Published: (2020) -
Anaplastic large cell lymphoma ALK-negative clinically mimicking alcoholic hepatitis - a review
by: Fernando Peixoto Ferraz de Campos, et al.
Published: (2013) -
Metallic implant-associated lymphoma: ALK-negative anaplastic large cell lymphoma associated with total knee replacement arthroplasty
by: Jai-Hyang Go
Published: (2023) -
Systemic ALK-positive anaplastic large cell lymphoma involving implant site: a fortuitous association
by: Mayur Parkhi, et al.
Published: (2021)